| scholarly article | Q13442814 |
| P50 | author | Michael J. Keating | Q66429598 |
| P2093 | author name string | Prithviraj Bose | |
| Varsha V Gandhi | |||
| P2860 | cites work | Bruton's tyrosine kinase separately regulates NFkappaB p65RelA activation and cytokine interleukin (IL)-10/IL-12 production in TLR9-stimulated B Cells | Q80705820 |
| PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia | Q89401183 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 | ||
| Targeted therapies in CLL: mechanisms of resistance and strategies for management | Q27002528 | ||
| Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase | Q27026912 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
| Ibrutinib in previously treated Waldenström's macroglobulinemia. | Q27853148 | ||
| Targets for Ibrutinib Beyond B Cell Malignancies | Q28087772 | ||
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | Q28306347 | ||
| Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes | Q47136959 | ||
| Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies | Q50277341 | ||
| Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. | Q51313042 | ||
| Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. | Q53376371 | ||
| Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias. | Q54258767 | ||
| Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. | Q54316160 | ||
| Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. | Q54328623 | ||
| Boldly Targeting Kinases without mutations. | Q54375805 | ||
| Cutaneous, Purpuric Painful Nodules Upon Addition of Ibrutinib to RCVP Therapy in a CLL Patient: A Distinctive Reaction Pattern Reflecting Iatrogenic Th2 to Th1 Milieu Reversal. | Q55025886 | ||
| Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. | Q55069337 | ||
| Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions | Q56657194 | ||
| Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking | Q73479515 | ||
| Nuclear factor-kappaB in cancer development and progression | Q29547879 | ||
| Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
| Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | Q30371806 | ||
| Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group | Q31097476 | ||
| Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial | Q33419580 | ||
| FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia | Q33425207 | ||
| Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study | Q33428297 | ||
| Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study | Q33432228 | ||
| Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL | Q33714712 | ||
| Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. | Q33794311 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
| Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib | Q34009064 | ||
| Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy | Q34020276 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia | Q34052075 | ||
| Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. | Q34172063 | ||
| Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
| The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia | Q34249777 | ||
| Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study. | Q34289493 | ||
| The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts | Q34310173 | ||
| Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells | Q34354339 | ||
| Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia | Q34504188 | ||
| Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells | Q35080394 | ||
| Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK | Q35156866 | ||
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
| Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib | Q35450520 | ||
| The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia | Q35567942 | ||
| Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia | Q35607285 | ||
| Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes | Q35625192 | ||
| Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants | Q35822277 | ||
| Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo | Q35849237 | ||
| Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 | ||
| Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study | Q35953518 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| The B-cell receptor signaling pathway as a therapeutic target in CLL. | Q36163034 | ||
| Treatment with Ibrutinib Inhibits BTK- and VLA-4-Dependent Adhesion of Chronic Lymphocytic Leukemia Cells In Vivo | Q36172601 | ||
| Initial treatment of CLL: integrating biology and functional status | Q36219647 | ||
| Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib | Q36253983 | ||
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib | Q36337598 | ||
| Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation | Q36368467 | ||
| Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement | Q36368492 | ||
| Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy. | Q36437030 | ||
| Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia | Q36490049 | ||
| A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies | Q36517276 | ||
| Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia | Q36597026 | ||
| Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study | Q36759124 | ||
| Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib | Q36782516 | ||
| Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. | Q36788133 | ||
| BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia | Q36799197 | ||
| Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia | Q36888218 | ||
| Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens | Q36900364 | ||
| Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition | Q36925503 | ||
| Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes | Q37226729 | ||
| Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). | Q37596620 | ||
| Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing | Q37635605 | ||
| Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy | Q37655012 | ||
| Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). | Q38083077 | ||
| Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor | Q38170076 | ||
| Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia. | Q38394750 | ||
| Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies | Q38927187 | ||
| Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels | Q39025763 | ||
| Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies | Q41524241 | ||
| Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib | Q41601558 | ||
| Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia | Q41865162 | ||
| Tec regulates platelet activation by GPVI in the absence of Btk. | Q42169529 | ||
| Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity | Q42401591 | ||
| Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. | Q42660684 | ||
| Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. | Q42703240 | ||
| Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia | Q43096794 | ||
| Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. | Q46711436 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| lymphocyte | Q715347 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| ibrutinib | Q5984881 | ||
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 1-12 | |
| P577 | publication date | 2016-10-11 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. |
| Q91735722 | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia |
| Q54977394 | A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. |
| Q92084382 | Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists |
| Q49714593 | Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia |
| Q59797097 | Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI |
| Q38818283 | Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. |
| Q46318389 | Recent therapeutic advances in chronic lymphocytic leukemia |
Search more.